Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Huge Seller Price Slash to Hit Nexium/Takecab; Rituxan, 8 Other Brands to Face Market Expansion Re-Pricing
January 18, 2018
-
REGULATORY Chuikyo OKs Special Re-Pricing for FY2018 Drug Price Revision, Here’s the List of Products
January 17, 2018
-
REGULATORY MHLW Health Policy Chief Wants Pricing Reform to Prod Drug Makers’ Overseas Expansions
January 17, 2018
-
BUSINESS Japan’s 1st Rituxan Biosimilar to Hit Shelves as Scheduled despite Patent Suit Filed
January 16, 2018
-
ORGANIZATION Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
-
REGULATORY Streamlining Regulations of Pharmaceutical Affairs to Be “a Top Priority” in 2018: MHLW Pharma Bureau Chief
January 12, 2018
-
BUSINESS Will Symbicort and Adoair Face Generic Entries This Year? Trade Group Has Seen High Hurdle for Inhaler Drugs
January 11, 2018
-
REGULATORY Balancing Innovation and Universal Coverage Was Key in Drug Pricing Reform: Health Minister
January 10, 2018
-
REGULATORY PMDA Chief Says Next Challenge Is to Boost Review Quality, Global Expansion Drive
January 9, 2018
-
BUSINESS Will Pricing Reform Spur Divestment of Off-Patent Brands in Japan? Next 3 Months Hold Key for Future Directions
January 1, 2018
-
BUSINESS Sawai Shooting for 12.7% Annual Growth for Upsher-Smith: Exec
December 27, 2017
-
BUSINESS MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?
December 26, 2017
-
REGULATORY “Comprehensive Strategy” Updated after 2 Years, MHLW to Mull Procedures for Info Handover for Brand-Name Meds Bowing Out of Market
December 25, 2017
-
ORGANIZATION JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
-
REGULATORY Chuikyo OKs Drug Pricing Reform Package; 30% Cap Set for “Category I” Companies Allowed to Maintain Full Prices
December 21, 2017
-
BUSINESS GSK Japan Pres. Kikuchi to Quit after Only 9 Months in Office
December 20, 2017
-
BUSINESS Gilead Aiming to Develop World’s First NASH Treatment, Hoping for Approval in 2020
December 20, 2017
-
REGULATORY (Update) Japan to Shave 720 Billion Yen through FY2018 Drug Price Revision
December 19, 2017
-
REGULATORY Govt to Draw Up “Plan to Strengthen Drug Discovery,” Boosting Budgets to Improve R&D Environment
December 18, 2017
-
BUSINESS Partnerships Hold Key to Success, Acquisition Not Our Goal: Takeda R&D Head
December 15, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…